$4.53
0.00% yesterday
Nasdaq, Dec 24, 10:50 pm CET
ISIN
US7995661045
Symbol
SANA

Sana Biotechnology Inc Stock price

$4.53
+0.99 27.97% 1M
+1.56 52.53% 6M
+2.90 177.91% YTD
+2.78 158.86% 1Y
+1.14 33.63% 3Y
-30.57 87.09% 5Y
-30.57 87.09% 10Y
-30.57 87.09% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.00 0.00%
ISIN
US7995661045
Symbol
SANA
Industry

New AI Insights on Sana Biotechnology Inc Insights AI Insights on Sana Biotechnology Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.1b
Net debt
positive
Cash
$153.1m
Shares outstanding
262.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.2
Financial Health
Equity Ratio
50.0%
Return on Equity
-106.5%
ROCE
-60.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-224.6m | $-207.7m
EBIT
$-240.0m | $-220.4m
Net Income
$-234.4m | $-235.3m
Free Cash Flow
$-158.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
21.1% | 18.7%
EBIT
21.9% | 19.2%
Net Income
23.3% | 11.8%
Free Cash Flow
42.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.6
Short interest
39.2%
Employees
194
Rev per Employee
$0.0
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Sana Biotechnology Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
87%
Hold
13%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
27% 27%
-
- Research and Development Expense 144 144
38% 38%
-
-225 -225
21% 21%
-
- Depreciation and Amortization 15 15
33% 33%
-
EBIT (Operating Income) EBIT -240 -240
22% 22%
-
Net Profit -234 -234
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
GlobeNewsWire
17 days ago
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology
Neutral
Seeking Alpha
22 days ago
Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral
Seeking Alpha
23 days ago
Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 194
Founded 2018
Website sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today